Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ProMIS Neurosciences Inc.
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
October 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
September 12, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
August 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
August 06, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
August 01, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
July 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
July 26, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
July 26, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
April 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 09, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 04, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
April 01, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 11, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
February 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 03, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 08, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 21, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 17, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Announces Completion of Continuance
July 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
July 10, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 30, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Tickers
PMN
TSX:PMN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.